PENTAM 300 Rx
Generic Name and Formulations:
Pentamidine isethionate 300mg/vial; lyophilized pwd for IM or IV inj after reconstitution.
Fresenius Kabi USA
Indications for PENTAM 300:
Pneumonia due to Pneumocystis carinii.
Adults and Children:
<4months: not recommended. Give by deep IM or IV inj. If administered by IV, must infused over 60–120 minutes. ≥4months: 4mg/kg once daily for 14–21 days. Therapy >21 days has been used; but may increase toxicity risk.
Hyper- or hypotension. Ventricular tachycardia. Hypo- or hyperglycemia. Hypocalcemia. Pancreatitis. Leukopenia. Thrombocytopenia. Anemia. Hepatic or renal dysfunction. Stevens-Johnson syndrome. Monitor BP, BUN, serum creatinine, blood glucose, CBC and platelets, liver function (eg, serum bilirubin, alkaline phosphatase, AST/ALT), serum calcium, ECG. Avoid extravasation. Have resuscitation equipment available. Pregnancy (Cat.C; avoid). Nursing mothers: not recommended.
Additive effects with concomitant other nephrotoxic drugs (eg, aminoglycosides, amphotericin B, cisplatin, foscarnet, vancomycin); monitor closely or avoid if possible.
Inj site reactions, severe hypotension, hypoglycemia, diabetes, acute pancreatitis, cardiac arrhythmias, nephrotoxic events (eg, renal dysfunction, elevated serum creatinine, azotemia, renal failure), leukopenia, elevated liver functions tests, anorexia/nausea, rash, pruritus.
Neurology Advisor Articles
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- Court Rules That U.S. Must Halt Sales of Pesticide Chlorpyrifos
- Both Abstinence and High Alcohol Use Linked to Dementia
- Therapeutic Plasma Exchange Effectively Improves Ambulation in Pediatric Transverse Myelitis
- TBI Linked to Increased Suicide Risk
- OnabotulinumtoxinA for Post-Stroke Spasticity: Treatment Strategies and Limitations